Vimarsana
Biggest News Aggregation in the World

Page 2 - Multi Center Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multi Center Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multi Center Study Today - Breaking & Trending Today

Treating Lower Back Pain - Vimarsana News

Treating Lower Back Pain

Lower back pain can be a disabling condition, as it can interfere with an individual’s ability to perform daily activities and may affect their quality of life.

New Study Finds Improved Long-Term Neurodevelopmental Outcomes for Extremely Premature Infants Fed Prolacta's Exclusive Human Milk Diet (EHMD) - Vimarsana News

New Study Finds Improved Long-Term Neurodevelopmental Outcomes for Extremely Premature Infants Fed Prolacta's Exclusive Human Milk Diet (EHMD)

/PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature...

New Study Finds Improved Long-Term Neurodevelopmental Outcomes for Extremely Premature Infants Fed Prolacta's Exclusive Human Milk Diet (EHMD) - Vimarsana News

New Study Finds Improved Long-Term Neurodevelopmental Outcomes for Extremely Premature Infants Fed Prolacta's Exclusive Human Milk Diet (EHMD)

Preterm Infants Who Received Prolacta's 100% Human Milk-Based Fortifiers as Part of an EHMD in the NICU Had Improved Developmental Outcomes at Age...

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children Seite 1 - Vimarsana News

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children Seite 1

03.11.2022 - Data being presented at the American Society of Nephrology (ASN) Kidney Week 2022 Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) ... Seite 1

Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30,...